JP2005511722A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005511722A5 JP2005511722A5 JP2003550791A JP2003550791A JP2005511722A5 JP 2005511722 A5 JP2005511722 A5 JP 2005511722A5 JP 2003550791 A JP2003550791 A JP 2003550791A JP 2003550791 A JP2003550791 A JP 2003550791A JP 2005511722 A5 JP2005511722 A5 JP 2005511722A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharmaceutical composition
- composition according
- active ingredient
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 9
- 239000004480 active ingredient Substances 0.000 claims 8
- 206010011401 Crohn's disease Diseases 0.000 claims 5
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 5
- 201000004681 psoriasis Diseases 0.000 claims 5
- 206010022114 Injury Diseases 0.000 claims 3
- 230000001404 mediated Effects 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- MVCOAUNKQVWQHZ-UHFFFAOYSA-N 1-(5-Tert-Butyl-2-P-Tolyl-2h-Pyrazol-3-Yl)-3-[4-(2-Morpholin-4-Yl-Ethoxy)-Naphthalen-1-Yl]-Urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 MVCOAUNKQVWQHZ-UHFFFAOYSA-N 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000009137 Behcet Syndrome Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 230000001154 acute Effects 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 201000006233 congestive heart failure Diseases 0.000 claims 2
- 238000007887 coronary angioplasty Methods 0.000 claims 2
- 200000000008 restenosis Diseases 0.000 claims 2
- 230000035939 shock Effects 0.000 claims 2
- 201000010874 syndrome Diseases 0.000 claims 2
- 201000006704 ulcerative colitis Diseases 0.000 claims 2
- 208000005298 Acute Pain Diseases 0.000 claims 1
- 206010001897 Alzheimer's disease Diseases 0.000 claims 1
- 206010002556 Ankylosing spondylitis Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000006673 Asthma Diseases 0.000 claims 1
- 201000008335 Behcet's disease Diseases 0.000 claims 1
- 210000004369 Blood Anatomy 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000010247 Contact Dermatitis Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010018651 Graft versus host disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 210000003714 Granulocytes Anatomy 0.000 claims 1
- 208000002183 Guillain-Barre Syndrome Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 1
- 210000000265 Leukocytes Anatomy 0.000 claims 1
- 210000004072 Lung Anatomy 0.000 claims 1
- 206010025169 Lyme disease Diseases 0.000 claims 1
- 208000010125 Myocardial Infarction Diseases 0.000 claims 1
- 206010051606 Necrotising colitis Diseases 0.000 claims 1
- 208000004995 Necrotizing Enterocolitis Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010061485 Respiratory fume inhalation disease Diseases 0.000 claims 1
- 208000006641 Skin Disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 231100000765 Toxin Toxicity 0.000 claims 1
- 206010048873 Traumatic arthritis Diseases 0.000 claims 1
- 201000001320 atherosclerosis Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 201000010816 bone resorption disease Diseases 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 231100000080 dermatitis contact Toxicity 0.000 claims 1
- 201000009273 endometriosis Diseases 0.000 claims 1
- 238000001631 haemodialysis Methods 0.000 claims 1
- 230000000322 hemodialysis Effects 0.000 claims 1
- 230000002757 inflammatory Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000009906 meningitis Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000000056 organs Anatomy 0.000 claims 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
Claims (13)
- 有効成分としてBIRB 796 BSを含有するサイトカイン介在性疾患治療用医薬組成物。
- 有効成分の各投与量が、150mg未満である、請求項1に記載の医薬組成物。
- 有効成分の各投与量が、4〜100mgである、請求項1に記載の医薬組成物。
- 有効成分の各投与量が、4、5、15、30、45、60、75又は100mgである、請求項1に記載の医薬組成物。
- サイトカイン介在性疾患が、煙の吸入により生じる肺の急性及び慢性炎症、子宮内膜症、ベーチェット病、ブドウ膜炎及び強直性脊椎炎、膵炎、ライム病、慢性関節リウマチ、炎症性腸疾患、敗血性ショック、変形性関節炎、クローン病、潰瘍性大腸炎、多発性硬化症、ギランバレー症候群、乾癬、移植片対宿主病、全身性エリテマトーデス、経皮的冠動脈形成術後の再狭窄、糖尿病、毒素性ショック症候群、アルツハイマー病、急性及び慢性の疼痛、接触性皮膚炎、アテローム性動脈硬化症、外傷性関節炎、糸球体腎炎、再潅流傷害、敗血症、骨吸収疾患、慢性閉塞性肺疾患、うっ血性心不全、喘息、脳卒中、心筋梗塞、温熱傷害、成人呼吸窮迫症候群(ARDS)、損傷に対する二次的他臓器傷害、急性炎症性コンポーネントを伴う皮膚病、急性化膿性髄膜炎、壊死性腸炎、及び血液透析、白血球交換療法又は顆粒球注入に関連する症候群から選ばれる、請求項1〜4のいずれか1項に記載の医薬組成物。
- 疾患が、慢性関節リウマチ、変形性関節炎、クローン病、乾癬、潰瘍性大腸炎、骨粗鬆症、慢性閉塞性肺疾患、経皮的冠動脈形成術後の再狭窄及びうっ血性心不全から選ばれる、請求項5に記載の医薬組成物。
- 疾患が、慢性関節リウマチ、変形性関節炎、クローン病及び乾癬から選ばれる、請求項6に記載の医薬組成物。
- 有効成分の各投与量が、30、50、60、70又は90mgである、請求項3に記載の医薬組成物。
- 疾患が、慢性関節リウマチ、クローン病及び乾癬から選ばれる、請求項8に記載の医薬組成物。
- 有効成分の各投与量が50又は70mgであり、疾患が慢性関節リウマチである、請求項8に記載の医薬組成物。
- 有効成分の各投与量が50、60、70又は90mgであり、疾患がクローン病である、請求項8に記載の医薬組成物。
- 有効成分の各投与量が30、50又は70mgであり、疾患が乾癬である、請求項8に記載の医薬組成物。
- サイトカイン介在性疾患治療用医薬組成物を製造するためのBIRB 796 BSの使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33924901P | 2001-12-11 | 2001-12-11 | |
US60/339,249 | 2001-12-11 | ||
PCT/US2002/039289 WO2003049742A1 (en) | 2001-12-11 | 2002-12-06 | Method for administering birb 796 bs |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005511722A JP2005511722A (ja) | 2005-04-28 |
JP2005511722A6 JP2005511722A6 (ja) | 2005-08-04 |
JP2005511722A5 true JP2005511722A5 (ja) | 2006-02-02 |
Family
ID=23328156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003550791A Pending JP2005511722A (ja) | 2001-12-11 | 2002-12-06 | Birb796bsの投与方法 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20030118575A1 (ja) |
EP (1) | EP1455791A1 (ja) |
JP (1) | JP2005511722A (ja) |
AU (1) | AU2002366644A1 (ja) |
CA (1) | CA2465759A1 (ja) |
WO (1) | WO2003049742A1 (ja) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040110755A1 (en) * | 2002-08-13 | 2004-06-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions |
FR2846328B1 (fr) * | 2002-10-23 | 2004-12-10 | Servier Lab | Nouveaux derives de l'imidazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
US20050148555A1 (en) * | 2003-08-22 | 2005-07-07 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating COPD and pulmonary hypertension |
MXPA06002853A (es) | 2003-09-11 | 2006-06-14 | Kemia Inc | Inhibidores citoquina. |
EP1824843A2 (en) | 2004-12-07 | 2007-08-29 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
JP2008523071A (ja) | 2004-12-07 | 2008-07-03 | ルーカス ファーマシューティカルズ, インコーポレイテッド | Mapキナーゼの尿素インヒビター |
US20060190282A1 (en) * | 2005-02-04 | 2006-08-24 | Jung Edward K | Providing risk mitigation in a virtual world |
US7774275B2 (en) * | 2005-02-28 | 2010-08-10 | Searete Llc | Payment options for virtual credit |
US20080215434A1 (en) * | 2005-02-04 | 2008-09-04 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Real world interaction with virtual world privileges |
US20070168214A1 (en) * | 2005-03-30 | 2007-07-19 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Virtual credit with transferability |
US7890419B2 (en) * | 2005-02-04 | 2011-02-15 | The Invention Science Fund I, Llc | Virtual credit in simulated environments |
US20070156509A1 (en) * | 2005-02-04 | 2007-07-05 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Real-world incentives offered to virtual world participants |
US20080092065A1 (en) * | 2005-02-04 | 2008-04-17 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Third party control over virtual world characters |
US8473382B2 (en) * | 2006-02-28 | 2013-06-25 | The Invention Science Fund I, Llc | Virtual collateral for real-world obligations |
US8566111B2 (en) * | 2005-02-04 | 2013-10-22 | The Invention Science Fund I, Llc | Disposition of component virtual property rights |
US20070198305A1 (en) * | 2005-03-30 | 2007-08-23 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Virtual credit with transferability |
US8271365B2 (en) * | 2005-02-04 | 2012-09-18 | The Invention Science Fund I, Llc | Real-world profile data for making virtual world contacts |
US7720687B2 (en) | 2005-10-03 | 2010-05-18 | The Invention Science Fund I, Llc | Virtual world property disposition after real-world occurrence |
US8457991B2 (en) * | 2005-02-04 | 2013-06-04 | The Invention Science Fund I, Llc | Virtual credit in simulated environments |
US20090099930A1 (en) * | 2005-02-04 | 2009-04-16 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Participation profiles of virtual world players |
US7937314B2 (en) * | 2005-10-21 | 2011-05-03 | The Invention Science Fund I | Disposition of component virtual property rights |
US20070013691A1 (en) * | 2005-07-18 | 2007-01-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Supervisory authority in virtual world environment |
US20090144148A1 (en) * | 2005-02-04 | 2009-06-04 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Attribute enhancement in virtual world environments |
US7958047B2 (en) | 2005-02-04 | 2011-06-07 | The Invention Science Fund I | Virtual credit in simulated environments |
US8512143B2 (en) * | 2005-07-18 | 2013-08-20 | The Invention Science Fund I, Llc | Third party control over virtual world characters |
US20080103951A1 (en) * | 2005-02-04 | 2008-05-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Virtual credit in simulated environments |
US20080270165A1 (en) * | 2005-02-04 | 2008-10-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Virtual world property disposition after real-world occurrence |
US20070118420A1 (en) * | 2005-02-04 | 2007-05-24 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Context determinants in virtual world environment |
US20090043683A1 (en) * | 2005-02-04 | 2009-02-12 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Virtual world reversion rights |
US20090138333A1 (en) * | 2005-02-04 | 2009-05-28 | Searete Llc, A Limited Liablity Of The State Of Delaware | Follow-up contacts with virtual world participants |
US8556723B2 (en) * | 2005-02-04 | 2013-10-15 | The Invention Science Fund I. LLC | Third party control over virtual world characters |
US8060829B2 (en) | 2005-04-15 | 2011-11-15 | The Invention Science Fund I, Llc | Participation profiles of virtual world players |
US20070078737A1 (en) * | 2005-02-28 | 2007-04-05 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Financial ventures based on virtual credit |
US20100016449A1 (en) * | 2006-12-21 | 2010-01-21 | Boehringer Ingelheim International Gmbh | Formulations with Improved Bioavailability |
EP3257862A1 (en) | 2016-06-16 | 2017-12-20 | ETH Zürich | Fibronectin-binding peptides for use in tumor or fibrosis diagnosis and therapy |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
LT3691620T (lt) | 2017-10-05 | 2022-09-26 | Fulcrum Therapeutics, Inc. | P38 kinazės inhibitoriai, sumažinantys dux4 ir pasrovinių genų raišką, skirti fshd gydymui |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4105766A (en) * | 1977-08-19 | 1978-08-08 | Sterling Drug Inc. | 4,5-Dihydro-5-oxopyrazolo[1,5-a]quinazoline-3-carboxylic acid derivatives |
HU185294B (en) * | 1980-12-29 | 1984-12-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing substituted urea derivatives |
US5162360A (en) * | 1991-06-24 | 1992-11-10 | Warner-Lambert Company | 2-heteroatom containing urea and thiourea ACAT inhibitors |
IL104369A0 (en) * | 1992-01-13 | 1993-05-13 | Smithkline Beecham Corp | Novel compounds and compositions |
US5783664A (en) * | 1993-09-17 | 1998-07-21 | Smithkline Beecham Corporation | Cytokine suppressive anit-inflammatory drug binding proteins |
ES2140561T3 (es) * | 1993-09-17 | 2000-03-01 | Smithkline Beecham Corp | Proteina de union de farmacos. |
US5869043A (en) * | 1993-09-17 | 1999-02-09 | Smithkline Beecham Corporation | Drug binding protein |
US5739143A (en) * | 1995-06-07 | 1998-04-14 | Smithkline Beecham Corporation | Imidazole compounds and compositions |
US5948885A (en) * | 1996-05-20 | 1999-09-07 | Signal Pharmaceuticals, Inc. | Mitogen-activated protein kinase p38-2 and methods of use therefor |
DE69733135T2 (de) * | 1996-06-10 | 2006-03-02 | Merck & Co., Inc. | Substituierte imidazole mit cytokinin-inhibirender wirkung |
US5851812A (en) * | 1997-07-01 | 1998-12-22 | Tularik Inc. | IKK-β proteins, nucleic acids and methods |
UA73492C2 (en) * | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
MXPA01008440A (es) * | 1999-02-22 | 2002-04-24 | Boehringer Ingelheim Pharma | Derivados heterociclicos policiclos como agentes anti-inflamatorios.. |
EP1305050A2 (en) * | 2000-07-24 | 2003-05-02 | Boehringer Ingelheim Pharmaceuticals Inc. | Improved oral dosage formulations |
WO2003015828A1 (en) * | 2001-08-20 | 2003-02-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea and a cyclodextrin |
JP2005506350A (ja) * | 2001-10-18 | 2005-03-03 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカイン阻害薬としての1,4−二置換ベンゾ−縮合尿素化合物 |
-
2002
- 2002-12-06 JP JP2003550791A patent/JP2005511722A/ja active Pending
- 2002-12-06 EP EP02804546A patent/EP1455791A1/en not_active Withdrawn
- 2002-12-06 CA CA002465759A patent/CA2465759A1/en not_active Abandoned
- 2002-12-06 WO PCT/US2002/039289 patent/WO2003049742A1/en active Application Filing
- 2002-12-06 AU AU2002366644A patent/AU2002366644A1/en not_active Abandoned
- 2002-12-06 US US10/313,667 patent/US20030118575A1/en not_active Abandoned
-
2007
- 2007-05-01 US US11/742,975 patent/US20070203141A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005511722A5 (ja) | ||
JP2005531584A5 (ja) | ||
JP2005523338A5 (ja) | ||
JP2005529890A5 (ja) | ||
JP2005506350A5 (ja) | ||
ES2251360T3 (es) | Compuestos heterociclicos aromaticos en calidad de agentes antiinflamatorios. | |
NZ591115A (en) | Azaindazole compounds as ccr1 receptor antagonists | |
JP2002539206A5 (ja) | ||
JP2008508303A5 (ja) | ||
JP2006514950A5 (ja) | ||
RU2007102576A (ru) | Новые индаэолкарбоксамиды и их применение | |
JP2010535218A5 (ja) | ||
HRP20110763T1 (hr) | Makrolidni konjugati s protuupalnom aktivnošću | |
JP2009531292A5 (ja) | ||
JP2004531571A5 (ja) | ||
JP2004533246A5 (ja) | ||
JP2009510051A5 (ja) | ||
NO20015082D0 (no) | Pulverinnåndingsapparat for kombinert medikament | |
EP2079732A1 (en) | 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist | |
JP2007529492A5 (ja) | ||
JP2007518801A5 (ja) | ||
JP2008516991A5 (ja) | ||
JP2006508966A5 (ja) | ||
JP2008533077A5 (ja) | ||
Gothner et al. | The use of double lumen cannula for veno-venous ECMO in trauma patients with ARDS |